Galera Therapeutics



HBM contact: Dr Ivo Staijen

Company status: public

Galera Therapeutics develops novel therapeutics that reduce severe side effects of radiation therapy in cancer patients. The lead molecule GC4419 has demonstrated efficacy in a phase IIb study in patients with head and neck cancer and has been granted Fast Track and Breakthrough Therapy designations by the U.S. FDA. 

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171